Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Microalbuminuria.

Nitin Khosla1, Pantelis A Sarafidis, George L Bakris

  • 1Department of Preventive Medicine, Hypertension/Clinical Research Center, Rush University Medical Center, 1700 West Van Buren Street, Suite 470, Chicago, IL 60612, USA.

Clinics in Laboratory Medicine
|August 30, 2006
PubMed
Summary

Microalbuminuria predicts cardiovascular events, not just kidney disease progression. Early detection and intervention are key for managing this marker in high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Factitious acidosis and severe hypoalbuminemia caused by unsuspected assay interference.

Clinical kidney journal·2021
Same author

Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease.

British journal of pharmacology·2021
Same author

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.

Circulation·2021
Same author

Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.

Journal of the American Society of Nephrology : JASN·2021
Same author

Mineralocorticoid receptor antagonists in diabetic kidney disease - mechanistic and therapeutic effects.

Nature reviews. Nephrology·2021
Same author

Longitudinal Blood Pressure Patterns and Chronic Kidney Disease Progression: An Evolving Paradigm.

Hypertension (Dallas, Tex. : 1979)·2021

Area of Science:

  • Nephrology
  • Cardiology
  • Diabetology

Background:

  • Microalbuminuria, initially a marker for diabetic nephropathy in type 1 diabetes, is now recognized for its broader cardiovascular implications.
  • It signifies increased cardiovascular risk beyond its association with kidney disease progression.

Purpose of the Study:

  • To review the role of microalbuminuria in atherosclerotic vascular disease.
  • To discuss assessment methods, risk factor associations, and pathophysiological links.
  • To explore its prognostic significance and therapeutic strategies for high-risk individuals.

Main Methods:

  • Literature review focusing on microalbuminuria's role in cardiovascular disease.
  • Analysis of assessment techniques and clinical practice guidelines.
  • Examination of pathophysiological mechanisms connecting microalbuminuria and vascular damage.

Main Results:

  • Microalbuminuria is a significant predictor of cardiovascular events.
  • It correlates with other cardiovascular risk factors and reflects underlying vascular damage.
  • Therapeutic interventions targeting albuminuria may reduce cardiovascular risk.

Conclusions:

  • Microalbuminuria serves as a crucial biomarker for cardiovascular risk assessment.
  • Understanding its link to atherosclerosis is vital for patient management.
  • Further research into therapeutic interventions is warranted to mitigate cardiovascular events.

Related Experiment Videos